Table 3. Overall survival (OS) . . . . .... | American Society of Hematology

Table 3.

Overall survival (OS)

					OS rate ± SE, %‡
	Log-rank test^*	Hazard ratio	95% CI†	97.5% CI†	12 mo	24 mo	36 mo
All patients	0.21	0.82	0.61-1.11	0.58-1.16
Control, n = 160					70 ± 3.6	51 ± 4.0	44 ± 4.0
HDC/IL-2, n = 160					78 ± 3.3	55 ± 4.0	48 ± 4.0
Patients in CR1	0.16	0.78	0.56-1.09	0.53-1.15
Control, n = 132					73 ± 3.9	53 ± 4.4	46 ± 4.4
HDC/IL-2, n = 129					80 ± 3.5	61 ± 4.3	55 ± 4.4
Patients in subsequent CR	> 0.5	1.00	0.52-1.93	0.47-2.13
Control, n = 28					59 ± 9.5	41 ± 9.5	33 ± 9.1
HDC/IL-2, n = 31					68 ± 8.4	32 ± 8.4	19 ± 7.1

					OS rate ± SE, %‡
	Log-rank test^*	Hazard ratio	95% CI†	97.5% CI†	12 mo	24 mo	36 mo
All patients	0.21	0.82	0.61-1.11	0.58-1.16
Control, n = 160					70 ± 3.6	51 ± 4.0	44 ± 4.0
HDC/IL-2, n = 160					78 ± 3.3	55 ± 4.0	48 ± 4.0
Patients in CR1	0.16	0.78	0.56-1.09	0.53-1.15
Control, n = 132					73 ± 3.9	53 ± 4.4	46 ± 4.4
HDC/IL-2, n = 129					80 ± 3.5	61 ± 4.3	55 ± 4.4
Patients in subsequent CR	> 0.5	1.00	0.52-1.93	0.47-2.13
Control, n = 28					59 ± 9.5	41 ± 9.5	33 ± 9.1
HDC/IL-2, n = 31					68 ± 8.4	32 ± 8.4	19 ± 7.1

Statistical analysis using the log-rank test, stratified by country and, if applicable, CR stratum.

Confidence intervals for the hazard ratios of the treatment arms.

OS rates are Kaplan-Meier estimates at each time point.